| |
|
|
|
CytomX Therapeutics Inc.  
|
|
6.18 1 (0.19%) |
11-20 16:00 |
|
Open: |
5.79 |
Pre close: |
5.18 |
Target:
|
7.57
|
|
High: |
6.34 |
Low: |
5.7 |
Resistance:
|
6.48
7.33
|
|
Volume: |
1,009,481 |
Market Cap: |
281M |
Support:
|
5.10
4.24
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
5.45
 |
MACD |
MACD(12,26):
|
-0.44 |
|
MA(20): |
5.90  |
Signal(12,26,9): |
-0.49 |
|
MA(100): |
8.59 |
Stochastic Oscillator |
%K(14,3):
|
28.47 |
|
MA(250): |
11.15 |
%D(3): |
15.11 |
|
Average Volume(K) |
3-Month: |
47381
|
52-Week |
High:
|
19.75 |
|
10-Days: |
48484 |
Low: |
5.10 |
|
RSI |
RSI(14):
|
50.09 |
Change(%): |
-52.1 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.190 |
Return on Equity (ttm) |
-82.6 |
Shares Out. (M) |
45.43 |
|
EPS Est. Current Year |
-1.490 |
Return on Assets (ttm) |
-14.5 |
Shares Float (M) |
41.13 |
|
EPS Est. Next Year |
-1.410 |
PEG Ratio |
3.04 |
% Held by Insiders |
2.50 |
|
EPS Est. Next Quarter |
-0.410 |
Qtrly Rev. Growth |
-14.4 |
% Held by Institutions |
86.29 |
|
Forward EPS |
-2.081 |
Gross Profit (p.s.) |
1.310 |
Shares Short (K) |
1830 |
|
Book Value (p.s.) |
1.810 |
EBITDA (p.s.) |
-2.131 |
P/E |
-2.82 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
3.41 |
|
Profit Margin |
-163.17 |
Operating Cash Flow
(M) |
-139.74 |
P/S |
4.61 |
|
Operating Margin |
-163.69 |
Levered Free Cash Flow
(M) |
-57.88 |
P/CF |
-2.01 |
|
|
|
|
|
|
